The objective of this study was to provide population-based estimates on the cost of HIV service provision in England and the use of dual or triple antiretroviral combination therapy.
Contemporary cost estimates of treating HIV-infected individuals by clinical stage of HIV infection (indexed to 1995/96 prices) were linked to the number of diagnosed HIV-infected individuals using statutory medical services in England during 1996.
Two cost measures were used :
The first one was based on average hospital prices derived from a number of English HIV units.
These results were compared with those estimated using standard unit costs obtained through specific costing studies performed at a national HIV referral centre.
Overall annual expenditure on HIV service provision was estimated for different treatment scenarios as was expenditure by clinical stage of HIV infection.
Using hospital prices, in 1996 the total annual cost estimate for HIV service provision amounted to £131m (range £83 m to £233 m), or £150 m (95% CI £126 m to £173 m) using standard costs, if all patients with HIV disease were treated with AZT monotherapy. (...)
Mots-clés Pascal : SIDA, Virose, Infection, Antiviral, Chimiothérapie, Traitement, Coût, Estimation, Angleterre, Grande Bretagne, Royaume Uni, Europe, Association médicamenteuse, Soin, Financement, Homme, Immunopathologie, Immunodéficit, Economie santé
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Antiviral, Chemotherapy, Treatment, Costs, Estimation, England, Great Britain, United Kingdom, Europe, Drug combination, Care, Financing, Human, Immunopathology, Immune deficiency, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0430102
Code Inist : 002B05C02D. Création : 25/01/1999.